- Home
- AKRO vs CERT Comparison
AKRO vs CERT Comparison
Compare AKRO & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- CERT
- Stock Information
- Founded
- AKRO 2017
- CERT 2008
- Country
- AKRO United States
- CERT United States
- Employees
- AKRO N/A
- CERT N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- CERT Retail: Computer Software & Peripheral Equipment
- Sector
- AKRO Health Care
- CERT Technology
- Exchange
- AKRO Nasdaq
- CERT Nasdaq
- Market Cap
- AKRO 2.8B
- CERT 2.3B
- IPO Year
- AKRO 2019
- CERT 2020
- Fundamental
- Price
- AKRO $39.85
- CERT $11.98
- Analyst Decision
- AKRO Strong Buy
- CERT Buy
- Analyst Count
- AKRO 9
- CERT 6
- Target Price
- AKRO $76.29
- CERT $15.60
- AVG Volume (30 Days)
- AKRO 1.1M
- CERT 2.8M
- Earning Date
- AKRO 05-16-2025
- CERT 05-05-2025
- Dividend Yield
- AKRO N/A
- CERT N/A
- EPS Growth
- AKRO N/A
- CERT N/A
- EPS
- AKRO N/A
- CERT N/A
- Revenue
- AKRO N/A
- CERT $394,498,000.00
- Revenue This Year
- AKRO N/A
- CERT $11.41
- Revenue Next Year
- AKRO N/A
- CERT $8.78
- P/E Ratio
- AKRO N/A
- CERT N/A
- Revenue Growth
- AKRO N/A
- CERT 9.37
- 52 Week Low
- AKRO $17.86
- CERT $8.64
- 52 Week High
- AKRO $58.40
- CERT $17.94
- Technical
- Relative Strength Index (RSI)
- AKRO 44.56
- CERT 45.14
- Support Level
- AKRO $41.60
- CERT $11.22
- Resistance Level
- AKRO $46.47
- CERT $12.30
- Average True Range (ATR)
- AKRO 2.26
- CERT 0.68
- MACD
- AKRO 0.08
- CERT -0.32
- Stochastic Oscillator
- AKRO 21.84
- CERT 18.37
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.